

Supplementary Information of the Materials and Methods

“Microglial depletion has no impact on disease progression in a mouse model of Machado-Joseph disease”

by Campos et al., 2022

Contents within the present file:

1. Supplementary Figures:

Figure S1. Schematic representation of the experimental design.

2. Supplementary References

1. Supplementary Figures




Figure S1. Schematic representation of the experimental design. The administration of PLX3397 was delivered to CMVMJD135 and wild-type (WT) mice every day by oral gavage at a dose of 40 mg/kg dissolved in 5 % DMSO and 25 % PEG300 in ddH₂O [47], from 18 to 21 weeks of age. Control animals (CMVMJD135 and WT) were given vehicle (5 % DMSO and 25 % PEG300 in ddH₂O) with the same frequency and route of administration [47]. Three weeks after treatment, groups of **a)** 4-5 animals per genotype/treatment were submitted to evaluation of density and morphological characteristics of microglial cells; and of **b)** 14-18 animals per genotype/treatment were used for behavioral analysis that were performed from week 6 to week 33.

2. Supplementary References

- [47] Merry, T.L., Brooks, A.E.S., Masson, S.W., Adams, S.E., Jaiswal, J.K., Jamieson, S.M.F., Shepherd, P.R. The csf1 receptor inhibitor pexidartinib (plx3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice. *International Journal of Obesity* 44(1), 245–253 (2020). doi:10.1038/s41366-019-0355-7.